"BE received the approval for restricted use in an emergency situation in adolescents aged 12 to less than 18 years based on interim results (of the ongoing phase 2/3 clinical study)," the company said in a statement.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/50WnIki
via IFTTT
0 comments:
Post a Comment